We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+19.33%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.67B
AUM Growth
+$125M
Cap. Flow
+$47M
Cap. Flow %
1.76%
Top 10 Hldgs %
52.29%
Holding
77
New
9
Increased
18
Reduced
19
Closed
10

Top Buys

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$132M
2
ARGX icon
argenx
ARGX
+$78.1M
3
IMA
ImageneBio Inc
IMA
+$45.7M
4
CGEM icon
Cullinan Oncology
CGEM
+$42.6M
5
MRUS
Merus
MRUS
+$34.1M

Top Sells

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$101M
2
AMRN
Amarin Corp
AMRN
+$60.8M
3
XNCR icon
Xencor
XNCR
+$55.2M
4
ALXO icon
ALX Oncology
ALXO
+$46.6M
5
RCUS icon
Arcus Biosciences
RCUS
+$30.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.46%
2 Financials 0.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FPRX
1
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$239M 8.95%
6,338,678
+5,300,000
+510% +$132M
OLMA icon
2
Olema Pharmaceuticals
OLMA
$1.02B
$221M 8.29%
6,661,503
– –
MRUS
3
DELISTED
Merus
MRUS
$152M 5.71%
7,285,071
+1,479,500
+25% +$34.1M
XOMA
4
DELISTED
Xoma
XOMA
$144M 5.4%
3,530,543
-651,700
-16% -$25.2M
RVMD icon
5
Revolution Medicines
RVMD
$40.2B
$135M 5.06%
2,943,049
+175,000
+6% +$7.85M
RPTX
6
DELISTED
Repare Therapeutics
RPTX
$114M 4.28%
3,722,398
+750,207
+25% +$25.5M
PTGX icon
7
Protagonist Therapeutics
PTGX
$8.78B
$103M 3.84%
3,959,451
-314,137
-7% -$7.95M
KYMR icon
8
Kymera Therapeutics
KYMR
$8.52B
$102M 3.83%
2,630,658
– –
RLAY icon
9
Relay Therapeutics
RLAY
$4.13B
$99.3M 3.72%
2,873,147
-200,000
-7% -$8.68M
ARGX icon
10
argenx
ARGX
$53.6B
$85.3M 3.2%
309,599
+247,108
+395% +$78.1M
EPIX
11
DELISTED
ESSA Pharma
EPIX
$84.5M 3.17%
2,908,326
-796,963
-22% -$18.5M
XENE icon
12
Xenon Pharmaceuticals
XENE
$6.1B
$62.3M 2.34%
3,481,778
-17,568
-0.5% -$298K
IONS icon
13
Ionis Pharmaceuticals
IONS
$8.56B
$61.3M 2.3%
1,364,461
– –
IDYA icon
14
IDEAYA Biosciences
IDYA
$3.43B
$61.3M 2.3%
2,607,969
-618,800
-19% -$11.9M
ACIU icon
15
AC Immune
ACIU
$226M
$57.1M 2.14%
7,504,579
-2,312,079
-24% -$16.5M
RCUS icon
16
Arcus Biosciences
RCUS
$3.55B
$52.7M 1.98%
1,876,122
-876,100
-32% -$30.5M
LXRX icon
17
Lexicon Pharmaceuticals
LXRX
$1.03B
$49.3M 1.85%
8,394,000
-2,569,000
-23% -$17.8M
KURA icon
18
Kura Oncology
KURA
$795M
$46.2M 1.73%
1,635,112
+389,200
+31% +$12.3M
IMA
19
ImageneBio Inc
IMA
$62.9M
$45.2M 1.69%
+133,305
New +$45.7M
FDMT icon
20
4D Molecular Therapeutics
FDMT
$542M
$44.7M 1.68%
1,031,070
-75,000
-7% -$3.32M
CGEM icon
21
Cullinan Oncology
CGEM
$1.01B
$43.7M 1.64%
+1,049,356
New +$42.6M
CTMX icon
22
CytomX Therapeutics
CTMX
$681M
$43.1M 1.62%
5,576,471
– –
MTEM
23
DELISTED
Molecular Templates, Inc.
MTEM
$36.1M 1.36%
190,953
+47,683
+33% +$8.36M
SPRO icon
24
Spero Therapeutics
SPRO
$68.3M
$31.5M 1.18%
2,137,978
-105,300
-5% -$1.85M
CBIO
25
Crescent Biopharma
CBIO
$528M
$28.7M 1.08%
95,443
– –
1
2 3 4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q1 2021 Portfolio in Review

As of Q1 2021, BVF Inc held 77 positions worth $2.67B, up 4.9% from $2.54B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

BVF Inc's Q1 2021 filing shows 9 new, 18 increased, 19 reduced and 10 closed positions. Its largest new stake was ImageneBio Inc: 133,305 shares worth $45.2M. The largest sale was Cytokinetics, an estimated $101M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials.

  • BVF Inc's largest Q1 2021 buy was ImageneBio Inc: 133,305 shares worth $45.2M.
  • BVF Inc added most to Five Prime Therapeutics, Inc. in Q1 2021, an estimated $132M increase.
  • BVF Inc's biggest Q1 2021 reduction was Amarin Corp, cutting an estimated $60.8M.
  • BVF Inc fully exited Cytokinetics in Q1 2021, selling an estimated $101M.
  • BVF Inc's ten largest holdings make up 52% of its $2.67B portfolio in Q1 2021.
  • BVF Inc opened 9 new positions and closed 10 in Q1 2021.
  • BVF Inc's portfolio value rose 4.9% quarter-over-quarter to $2.67B.

Based on BVF Inc's 13F filing for Q1 2021, filed 17 May 2021.